In veterinary oral solid dosage manufacturing, direct compression of fipronil pharma grade API into tablets requires pre-characterization of particle-size distribution, bulk density, flow function coefficient, and compaction behaviour because the API has reported aqueous solubility of 1.9 mg/L at 20 °C, a log P of 4.0, and a molecular weight of 437.15 g/mol. Low-dose direct compression is evaluated only when label claim and tablet mass permit the API to constitute 1.0–10.0% w/w of the core without excessive segregation risk. Compliance during development is anchored to USP <905> and Ph. Eur. 2.9.40 for content uniformity, USP <701> and Ph. Eur. 2.9.1 for disintegration, and 21 CFR 211.110 for in-process weight and density control. When no target-market monograph for fipronil tablets is available, the finished product specification is derived from these general chapters and registration commitments. A platform blend commonly comprises microcrystalline cellulose 45–60% w/w, lactose monohydrate 20–35% w/w, crospovidone 2–5% w/w, colloidal silicon dioxide 0.5–1.0% w/w, and magnesium stearate 0.5–1.0% w/w. The API is first pre-blended with an equal mass of filler and passed through a 500 μm stainless-steel sieve. The pre-blend is transferred to a bin blender and mixed for 15–25 min at 12–18 rpm, followed by lubricant addition for the final 3–5 min to avoid over-lubrication. Over-lubrication is a critical process conflict because fipronil is hydrophobic and excessive magnesium stearate can delay tablet disintegration and dissolution. Compression is performed on a rotary tablet press at main compression force 8–20 kN, with tablet hardness held at 60–100 N and friability below 0.8%. The terminal film-coated tablet uses an HPMC-based coating at 2–4% w/w weight gain and must deliver content uniformity AV ≤ 15 and disintegration ≤ 15 min in water at 37 ± 2 °C. Direct compression is abandoned when the API-filler blend shows flow function coefficient below 4 or when assay variance cannot be controlled by process adjustment alone.

What Drying Parameters Hold Fipronil Impurities Within Pharmacopoeial Limits During Wet Granulation?

When direct compression fails content uniformity acceptance value AV ≤ 15, wet granulation becomes the preferred pathway for fipronil oral granules and tablet intermediates. High-shear granulation is carried out in a top-drive granulator with dry mixing for 2 min at impeller speed 200–400 rpm and chopper speed 1500–3000 rpm. The binder system is commonly an aqueous hypromellose solution at 2–4% w/w solids, added at 15–25 g/min per kg dry mass to a total liquid-to-solid ratio of 0.15–0.25. Extragranular components include lactose monohydrate 55–75% w/w, crospovidone 2–5% w/w, and magnesium stearate 0.5–1.0% w/w. Residual solvent control follows VICH GL18 and ICH Q3C, with ethanol as the only organic solvent if a hydroalcoholic binder is required. The wet mass is passed through a 2.0 mm screen and dried in a fluid-bed dryer with inlet air temperature 50–70 °C until loss on drying reaches 1.5–3.0% w/w. Drying temperature is not increased beyond 70 °C without fipronil-specific thermal stability data, because impurity formation must be held within registration limits. Dried granules are milled through a 0.8–1.2 mm conical mill and screened to D50 of 200–500 μm; fines below 75 μm are held at ≤ 15% to prevent flow variability during subsequent compression or sachet filling. Particle-size testing follows USP <786> and Ph. Eur. 2.9.38. The terminal granule product is filled into aluminium sachets as an oral granule or compressed into tablets after extragranular blending. In-process moisture, blend uniformity, and granule size are controlled under 21 CFR 211.110, and the finished product must meet content uniformity AV ≤ 15.

During low-humidity encapsulation campaigns, the charge-to-mass ratio of the API-filler blend governs weight variation and content uniformity for fipronil hard gelatin capsules. Capsule size is selected by fill weight, commonly 80–300 mg for small-animal oral administration, with fipronil loading determined by target dose and assay. The dry blend platform comprises API, pregelatinized starch 20–40% w/w, microcrystalline cellulose 20–30% w/w, croscarmellose sodium 3–5% w/w, colloidal silicon dioxide 0.5–1.5% w/w, and sodium stearyl fumarate 0.5–1.5% w/w. Sodium stearyl fumarate is selected in some capsule runs to reduce hydrophobic dissolution delay at low shear. The API is first triturated with one part colloidal silicon dioxide and passed through a 425 μm screen to deagglomerate and reduce static charge. The screened preblend is discharged into a bin blender and mixed for 18–22 min at 12–18 rpm, with lubricant added for the final 4–5 min. The encapsulation room is held at 20–25 °C and 35–45% RH, because low humidity reduces electrostatic bridging on dosator or tamping-pin equipment. Automatic capsule fillers are operated with fill weight control of ± 3%, and sorted capsules are checked by metal detection and vision systems. Dissolution is evaluated by USP <711> or Ph. Eur. 2.9.3 in surfactant-containing medium, because fipronil does not provide adequate sink conditions in plain water. Content uniformity is controlled by USP <905> or Ph. Eur. 2.9.40, and moisture content of the filled capsules is held at 13–16% for hard gelatin shell stability. The terminal blister pack uses PVC/PVDC foil; if gelatin cross-linking is observed during stability, HPMC capsule shells are substituted. The process boundary is defined by electrostatic charge and blend segregation, not by API chemical instability, because the low-dose blend can segregate if relative humidity rises above 45% or if silicon dioxide level falls below 0.5% w/w.

The following compendial anchor matrix is used for platform evaluation across the four dosage form families. The limits shown are screening targets, not approved finished product specifications unless registered.

When Aqueous Solubility Below 2 mg/L Forces Non-Aqueous Parenteral Development

Formulation of an injectable solution with fipronil pharma grade API cannot begin from aqueous dilution alone. Reported aqueous solubility of 1.9 mg/L at 20 °C and log P of 4.0 place the API in the practically insoluble class, so simple water-for-injection solutions are not feasible at the intended veterinary injectable concentration. Development therefore screens binary and ternary water-miscible solvent systems under cGMP, using solubility data generated by shake-flask method followed by HPLC assay. Candidate vehicles include propylene glycol, PEG 400, glycerol formal, and benzyl alcohol; water may be included only if the final mixture retains sufficient solubilizing capacity after 48 h at 2–8 °C. Published data for fipronil-specific injectable solution systems is limited, so solubility screening and precipitation risk assessment are required rather than interpolation from prior art. Dissolution of the API in the non-aqueous vehicle is performed at 40–60 °C under nitrogen, because oxygen exposure at elevated temperature can accelerate degradation. The solution is cooled to 20–25 °C and filtered through a 0.2 μm PVDF or PTFE-compatible sterile filter; nylon filters are avoided if ketone-containing solvents are used. Sterile filtration is preferred when terminal moist-heat sterilization at 121 °C for 15 min is not supported by fipronil stability data. Filling into Type I borosilicate glass or polymer vials is conducted in an ISO 7 cleanroom under ISO 5 unidirectional airflow, with aseptic process validation per 21 CFR 211.113. Finished product testing includes sterility by USP <71> or Ph. Eur. 2.6.1, bacterial endotoxins by USP <85> or Ph. Eur. 2.6.14, and particulate matter by USP <788> or Ph. Eur. 2.9.19. The critical process conflict is dilution-induced precipitation: if the formulation is mixed with 0.9% sodium chloride injection or physiological buffer in in-use compatibility testing, visible precipitation indicates that the solvent system must be adjusted or the product must be administered without dilution. A non-aqueous injectable solution is therefore acceptable only when clarity, assay, and subvisible particle counts remain within specification after simulated injection. The terminal product is a particle-free solution for subcutaneous injection, with label-restricted in-use handling to prevent precipitation at the needle tip.

Parenteral Suspension Milling and Particle-Size Narrowing for Subcutaneous Administration

Because non-aqueous vehicles can introduce injection-site irritancy or species-specific intolerance, a sterile aqueous suspension may be evaluated for fipronil pharma grade API. The suspension strategy avoids high solvent exposure but shifts process risk to particle-size control and physical stability. The formulation platform includes micronized API, polysorbate 80 0.1–0.5% w/v, sodium carboxymethylcellulose 0.5–1.5% w/v, and mannitol as tonicity adjuster; the final aqueous phase is water for injections. The API is first wet with the surfactant solution and dispersed by rotor-stator mixing at 10,000–15,000 rpm for 5–10 min. The coarse dispersion is then passed through a bead mill charged with 0.2–0.5 mm yttrium-stabilized zirconia beads, with jacket cooling to hold process temperature below 25 °C. Milling continues until the suspension reaches D50 below 1 μm and D90 below 10 μm; particle size is verified by laser diffraction and subvisible particle counts are checked by USP <788> or Ph. Eur. 2.9.19. Because high-energy milling can generate amorphous surface domains that disappear during storage and drive Ostwald ripening, the suspension is annealed at 40–50 °C for 4–6 h under gentle agitation before final filling. The annealed suspension is filled into Type I glass vials and terminal sterilization is selected only if fipronil thermal stability data support moist heat; otherwise aseptic filling through a 0.2 μm filter is used, which requires that the API is already sterile and the suspending agent is compatible with filtration. Viscosity is measured by Brookfield viscometer at 25 ± 0.5 °C and is typically targeted below 100 mPa·s to maintain injectability through a 21 G needle. Sterility is confirmed by USP <71> or Ph. Eur. 2.6.1, and endotoxin control follows USP <85> or Ph. Eur. 2.6.14. Published data for fipronil-specific suspension formulations is limited; the particle-size and viscosity boundaries above are platform targets that must be confirmed by registration stability studies. The terminal product is a sterile aqueous suspension for subcutaneous or intramuscular injection, with syringeability and resuspendability limits defined in the registration dossier. The formulation is not suitable for intravenous administration because particle size and vehicle composition are not designed for rapid systemic dilution.

Oral Granule Multi-Particulate Systems for Precision Dosing in Small Animals

Oral granule multi-particulate systems are developed when dose adjustment by body weight requires the finest possible dose increments and a tablet cannot be split. Fluid-bed layering of fipronil onto inert cores is the primary process, using a Wurster bottom-spray chamber with sugar spheres of 250–700 μm. The API is dispersed in an aqueous hypromellose solution of 5% w/w solids, and sprayed at 5–12 g/min per kg core charge at inlet air temperature 45–60 °C and atomization pressure 1.0–2.0 bar. The coated cores are given a protective seal coat of hypromellose at 1–2% w/w weight gain, followed by drying in the same fluid bed to loss on drying below 3.0% w/w. Content uniformity is measured by USP <905> or Ph. Eur. 2.9.40, with acceptance value AV ≤ 15. Particle-size distribution is controlled by USP <786> or Ph. Eur. 2.9.38, and dissolution is evaluated by USP <711> or Ph. Eur. 2.9.3 only after the granule has been shown to release under fed-state conditions, because oral administration may be on moist food. Residual solvent analysis follows VICH GL18 and ICH Q3C, with ethanol and isopropanol tracked if organic co-solvents are used in the layering dispersion. The terminal product is a free-flowing granule in sachet or metering closure presentation, with no need for sterile manufacturing but with bioburden and moisture limits appropriate for non-sterile oral veterinary products. The main process bottleneck is spray-rate control: excessive spray rate causes agglomeration and loss of discrete multi-particulates, while insufficient spray rate extends processing time and may create spray-dried fines. Real-time monitoring of outlet air humidity and particle-size trend is therefore required to maintain batch-to-batch reproducibility. The process boundary is set by core size distribution and layering dispersion viscosity; if dispersion viscosity exceeds 300 mPa·s, nozzle blockage and twin-fluid atomization failure become more likely.